Castrate-resistant Prostate Cancer Market Size Worth $14.5 billion by 2026 - KBV Research

Castrate-resistant Prostate Cancer Market Size Worth $14.5 billion by 2026 - KBV Research
According to a new report Global Castrate-Resistant Prostate Cancer Market, published by KBV research, The Global Castrate-resistant Prostate Cancer Market size is expected to reach $14.5 billion by 2026, rising at a market growth of 8.3% CAGR during the forecast period.

Immunotherapy therapy is among the crucial therapeutic options and has the possibility to affect mCRPC. As per the Dendreon Pharmaceuticals, Provenge is given to approximately 40,000 men suffering from advanced prostate cancer. It is the autologous cellular immunotherapy for curing asymptomatic or mCRPC.

The radiation therapy category is expected to be the fastest-growing category during the forecast period. On the basis of the drug delivery method, the market is categorized into injectable and oral therapy segments.

The market for castrate-resistant prostate cancer is anticipated to increase at a notable rate over the forecast period in Europe. This is credited to the integrated efforts of many governments & private institutions like the European Organization for Research and Treatment of Cancer (EORTC) and the European Medicines Agency (EMA), to make distinctive programs aiming for different methodologies in drug development.

The North America market dominated the Global Castrate-resistant Prostate Cancer Market by Region in 2019. In the Asia Pacific, the market for castrate-resistant prostate cancer is estimated to propel at a significant rate over the forecast period. It is due to the presence of key oncology companies and rising R&D investments in countries like China and Japan. On the other hand, it led to the increasing development of prostate cancer drugs. Furthermore, the cost of clinical trials is less in developing countries than in developed countries.

Full Report

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)

Global Castrate-Resistant Prostate Cancer Market Segmentation

By Therapy

  • Hormonal Therapy

  • Immunotherapy

  • Chemotherapy

  • Radiotherapy

By Geography

North America

  • US

  • Canada

  • Mexico

  • Rest of North America


  • Germany

  • UK

  • France

  • Russia

  • Spain

  • Italy

  • Rest of Europe

Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Rest of Asia Pacific


  • Brazil

  • Argentina

  • UAE

  • Saudi Arabia

  • South Africa

  • Nigeria

  • Rest of LAMEA

Companies Profiled

  • Sanofi S.A.

  • Johnson and Johnson

  • Pfizer, Inc.

  • Bayer AG

  • Abbott Laboratories

  • GlaxoSmithKline PLC (GSK)

  • Northwest Biotherapeutics, Inc.

  • Active Biotech AB

  • Astellas Pharma, Inc.

  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)


FECHA: a las 11:34h (49 Lecturas)

TAGS: castrate-resistant prostate cancer market, castrate-resistant prostate cancer market share, castrate-resistant prostate

EN: Bienestar